U.S. Viscosupplementation Market Size, Share, and Growth Forecast, 2026 - 2033

The U.S. viscosupplementation market size is likely to be valued at US$2.0 billion in 2026 and is expected to reach US$2.9 billion by 2033, growing at a CAGR of 5.4% during the forecast period from 2026 to 2033, driven by the substantial burden of osteoarthritis and continued demand for non-surgical treatment options for joint pain.

In 2025, a CDC analysis found that 33.2 million U.S. adults had osteoarthritis, representing the most common arthritis subtype among diagnosed arthritis cases. OA prevalence also increased sharply with age, reaching 34.4% among adults aged 75 years and older.

Driver- Preference for Non-Surgical, Minimally Invasive Therapies

The preference for non-surgical and minimally invasive approaches is supporting demand for viscosupplementation in the U.S., particularly among patients seeking symptom management before considering joint replacement. Viscosupplementation delivers hyaluronic acid directly into the joint and can be performed during an outpatient or office-based visit. Cleveland Clinic notes that knee gel injections are generally administered as a minimally invasive procedure and may provide symptom relief lasting several months.

This treatment positioning makes viscosupplementation relevant for patients with persistent osteoarthritis symptoms who have not achieved adequate relief from conservative measures. The driver is reinforced by the growing clinical focus on managing osteoarthritis while postponing or avoiding invasive procedures when appropriate.

Viscosupplementation can be repeated according to product-specific protocols, with treatment courses ranging from single injections to multiple injections. Cleveland Clinic reports that some patients may experience relief for about six months following treatment. Clinical adoption remains influenced by physician assessment, disease severity, and treatment guidelines. The American Academy of Orthopaedic Surgeons (AAOS) continues to evaluate hyaluronic acid injections within evidence-based knee osteoarthritis management recommendations.

Restraint - Variable Clinical Guideline Recommendations and Efficacy Debates

Variable clinical recommendations represent a significant restraint because physicians and healthcare systems may differ in their willingness to use hyaluronic acid injections for osteoarthritis. The AAOS guideline for knee osteoarthritis states that intra-articular hyaluronic acid injections are not recommended for routine use in symptomatic knee osteoarthritis. Such recommendations can influence treatment pathways, physician preferences, and payer considerations, particularly when alternative interventions are available.

Manufacturers face the challenge of demonstrating consistent clinical benefits across different patient populations, disease severities, injection schedules, and product formulations. Evidence differences across joints add another layer of uncertainty to clinical adoption.

In January 2024, the AAOS updated its hip osteoarthritis guidance and strongly recommended that intra-articular hyaluronic acid not be considered for symptomatic hip osteoarthritis because evidence did not demonstrate meaningful benefit. The AAOS guidance for glenohumeral osteoarthritis reports strong evidence showing no benefit from hyaluronic acid treatment. These recommendations can restrict expansion beyond knee applications and reinforce ongoing debates regarding efficacy, appropriate patient selection, and clinical value.

Opportunity - Single-Injection and Advanced Cross-Linked Products

Single-injection viscosupplementation presents an important opportunity because fewer treatment visits can improve convenience for patients and simplify administration for healthcare providers. Product formulations using cross-linked hyaluronic acid can be designed to provide longer-lasting residence within the joint compared with some conventional formulations.

A published clinical review describes Durolane as a single-injection, cross-linked sodium hyaluronate product and reports improvements in pain, physical function, and quality of life in knee osteoarthritis studies. Such formulations can support differentiation in a competitive U.S. market where convenience and treatment duration are important considerations.

Advanced formulations also create opportunities for manufacturers to differentiate products through molecular characteristics, cross-linking technologies, injection frequency, and patient-specific treatment positioning. The AAOS evidence review includes research evaluating single intra-articular injections of lightly cross-linked hyaluronic acid for symptomatic knee osteoarthritis. At the same time, product development must remain aligned with clinical evidence and regulatory requirements. Continued innovation in formulation design, combined with real-world evidence and improved patient selection, could strengthen the commercial positioning of single-injection products while addressing convenience-related barriers associated with multi-injection treatment courses.

Product Type Insights

Single injection viscosupplementation is expected to lead the U.S viscosupplementation market, accounting for approximately 60% of revenue in 2026, driven by fewer treatment visits, greater patient convenience, and simplified administration. The segment benefits from increasing availability of products specifically designed for single-dose administration. A recent example is HYMOVIS ONE, for which the U.S. FDA approved a labeling supplement in April 2025 for treatment of knee osteoarthritis pain after inadequate response to conservative therapy. The FDA documentation confirms that HYMOVIS ONE is administered as a single intra-articular injection, reinforcing the availability and clinical positioning of single-injection viscosupplementation products in the U.S. market.

Three injection viscosupplementation is likely to represent the fastest-growing segment over the forecast period, supported by established multi-dose treatment protocols, physician familiarity, and continued utilization among patients requiring sequential hyaluronic acid administration. Its growth is also sustained by the broad availability of established products and clinician experience with repeated intra-articular treatment. The AAOS Clinical Practice Guideline for knee osteoarthritis, while not recommending routine hyaluronic acid use, recognizes intra-articular interventions within the broader non-arthroplasty treatment landscape, supporting continued clinical evaluation of appropriate patient populations.

Application Insights

Knee osteoarthritis is projected to lead the market, capturing around 80% of the revenue share in 2026, supported by viscosupplementation products that have established regulatory indications and clinical use concentrated on knee pain associated with osteoarthritis. The knee also represents a major site of osteoarthritis-related functional impairment, creating substantial demand for non-surgical management options. The FDA's April 2025 approval update for HYMOVIS ONE specifically indicates its use for treating pain associated with osteoarthritis of the knee in patients who have not responded adequately to conservative non-pharmacologic therapy or simple analgesics.

Shoulder osteoarthritis is likely to be the fastest-growing application in 2026, driven by increasing clinical attention to non-surgical management of shoulder joint degeneration and growing use of image-guided intra-articular procedures. Expansion remains relatively selective because evidence and regulatory positioning differ from those established for knee osteoarthritis. The AAOS maintains a dedicated Clinical Practice Guideline for glenohumeral joint osteoarthritis, reflecting continued clinical evaluation of treatment options for shoulder disease. The evidence base remains a consideration for viscosupplementation adoption, making appropriate patient selection particularly important.

Distribution Channel Insights

Hospital pharmacies are estimated to lead the U.S. viscosupplementation market, accounting for approximately 55% of revenue in 2026, due to the clinical nature of viscosupplementation administration and the involvement of orthopedic, rheumatology, and other healthcare professionals. Hospital-based channels provide controlled product handling and facilitate coordination between prescribing clinicians and administration services. Viscosupplementation products are generally administered through intra-articular injection by trained healthcare professionals rather than taken independently by patients.

Online pharmacies are likely to represent the fastest-growing segment in 2026, driven by expanding digital healthcare infrastructure, improved prescription fulfillment capabilities, and increasing consumer familiarity with online medication purchasing. Digital channels can improve convenience and support product access, although viscosupplementation remains distinct from conventional oral medicines as administration generally requires a healthcare professional. The U.S. FDA recognizes that legally operating online pharmacies can provide convenience and other benefits while emphasizing the importance of using legitimate, licensed sources.

The U.S. viscosupplementation market exhibits a moderately fragmented structure, driven by the presence of established pharmaceutical and medical device companies alongside specialized orthopedic players. Competition is centered on hyaluronic acid-based products, injection frequency, clinical positioning, physician adoption, and distribution strength. With key leaders including Sanofi S.A., Ferring B.V., Fidia Pharma USA Inc., Zimmer Biomet Holdings Inc., and OrthogenRx Inc., the market features both established portfolios and specialized viscosupplementation offerings.

These players compete through product differentiation, formulation innovation, injection-frequency options, clinical evidence, physician relationships, and broad distribution networks. Single-injection products remain an important area of competition, while multi-injection therapies continue to maintain established clinical positions. Anika's 2025 filing highlights continued U.S. market leadership of its Monovisc and Orthovisc portfolio and identifies Cingal as its next-generation single-injection product combining cross-linked hyaluronic acid with a corticosteroid.

Key Industry Developments:

• In January 2026, Joint Relief Institute highlighted viscosupplementation as a leading non-surgical knee osteoarthritis treatment, emphasizing advances in high-molecular-weight hyaluronic acid formulations and precision-guided injection techniques.
• In December 2025, Cipla partnered with Stempeutics Research to launch Ciplostem, a single-dose intra-articular therapy for Grade II and III knee osteoarthritis, marking Cipla’s entry into orthobiologic treatments.